^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

A novel SLC8A1-ALK fusion in lung adenocarcinoma confers sensitivity to alectinib: A case report

Published date:
08/11/2022
Excerpt:
...we reported a patient with advanced lung adenocarcinoma harboring a SLC8A1-ALK fusion who benefited from first-line treatment with alectinib. After 2 months of taking alectinib, the targeted lung lesions and intrahepatic metastases regressed significantly.
DOI:
https://doi.org/10.1515/biol-2022-0090